163 terminated. 163 Phase 2, 33 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 163 | Terminated 163 |
| Phase 1 | 33 | Terminated 33 |
| Phase 3 | 4 | Terminated 4 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study to Pioneer Study 6058-SCD-101 Pociredir - Sickle Cell Disease | Phase 2 | Terminated | Fulcrum Therapeutics | 1 | 2026-03-30 | 2026-10-28 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease ALXN1820 - Sickle Cell Disease (SCD) | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 2 | 2023-02-22 | 2025-01-13 |
| Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria BCX9930 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Terminated | BioCryst Pharmaceuticals | 28 | 2023-01-18 | 2025-10-24 |
| GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) Osivelotor - Sickle Cell Disease | Phase 2 / Phase 3 | Terminated | Pfizer | 47 | 2023-01-05 | 2026-03-19 |
| AB1 in Adult Patients With Sickle Cell Disease (SCD) AB1 - Sickle Cell Disease | Phase 1 / Phase 2 | Terminated | Nirmish Shah | 16 | 2022-12-05 | 2026-10-15 |
| A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) Etavopivat - Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R | Phase 2 | Terminated | Forma Therapeutics, Inc. | 17 | 2022-11-15 | 2026-09-03 |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers Fludarabine, Cyclophosphamide, Thiotepa - Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2022-10-06 | 2025-01-01 |
| Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease MGTA-145, Plerixafor - Sickle Cell Disease | Phase 2 | Terminated | Ensoma | 1 | 2022-06-24 | 2025-07-25 |
| Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients Canakinumab Injection - Anemia, Myelodysplastic Syndromes | Phase 2 | Terminated | University of Leipzig | 10 | 2022-04-26 | 2024-05-06 |
| Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 CA-4948 - Myelodysplastic Syndromes, Anemia | Phase 2 | Terminated | University of Leipzig | 38 | 2022-01-01 | 2024-08-13 |
| Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders Iptacopan - Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD) | Phase 2 | Terminated | Novartis Pharmaceuticals | 19 | 2021-12-21 | 2025-10-16 |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy Eculizumab, Ravulizumab, BCX9930 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Terminated | BioCryst Pharmaceuticals | 12 | 2021-12-06 | 2025-03-07 |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy Placebo, BCX9930 monotherapy - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Terminated | BioCryst Pharmaceuticals | 12 | 2021-10-26 | 2026-10-29 |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma INCB000928 - Myelodysplastic Syndromes, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 22 | 2021-08-19 | 2025-10-22 |
| Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia Decitabine - Refractory Aplastic Anemia | Phase 2 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 3 | 2021-04-22 | 2026-02-11 |
| A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease Voxelotor - Sickle Cell Disease, Sickle Cell Nephropathy | Phase 1 / Phase 2 | Terminated | University of Illinois at Chicago | 12 | 2021-03-16 | 2025-04-03 |
| Thrombosomes® in Bleeding Thrombocytopenic Patients Study Thrombosomes, Liquid Stored Platelets (LSP) - Thrombocytopenia, Hematologic Malignancy | Phase 2 | Terminated | Cellphire Therapeutics, Inc. | 21 | 2021-03-05 | 2023-05-25 |
| Mechanisms of EPO-induced Hypertension Darbepoetin - Chronic Kidney Disease, Blood Pressure | Phase 2 | Terminated | VA Office of Research and Development | 27 | 2021-01-04 | 2025-12-15 |
| A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS TP-0184 - Anemia in Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 2 | 2020-12-28 | 2023-11-09 |
Showing 20 of 163. Sign in to see all of them.
Anemia, Sickle Cell (46) · Myelodysplastic Syndromes (29) · Anemia, Refractory, with Excess of Blasts (24) · Leukemia (20) · Leukemia, Myeloid, Acute (19) · Anemia, Aplastic (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Thalassemia (12) · Leukemia, Myelomonocytic, Chronic (10) · Multiple Myeloma (10) · Anemia, Iron-Deficiency (9) · Anemia, Refractory (9) · Lymphoma (9) · Kidney Failure, Chronic (8)
Hemic and Lymphatic Diseases (163) · Hematologic Diseases (160) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (69) · Anemia, Hemolytic (63) · Bone Marrow Diseases (61) · Genetic Diseases, Inborn (60) · Anemia, Hemolytic, Congenital (54) · Pathological Conditions, Signs and Symptoms (49) · Hemoglobinopathies (47) · Pathologic Processes (44) · Neoplasms (39) · Neoplasms by Histologic Type (37) · Disease Attributes (34) · Chronic Disease (31)
Cyclophosphamide (18) · Epoetin Alfa (15) · fludarabine phosphate (15) · Whole-Body Irradiation (13) · Busulfan (11) · fludarabine (10) · Antilymphocyte Serum (8) · Tacrolimus (8) · Alemtuzumab (6) · Darbepoetin alfa (6) · Mycophenolic Acid (6) · Hydroxyurea (5) · Methotrexate (5) · Peripheral Blood Stem Cell Transplantation (5) · thymoglobulin (5)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (9) · Baylor College of Medicine (7) · Fred Hutchinson Cancer Center (7) · BioCryst Pharmaceuticals (4) · Masonic Cancer Center, University of Minnesota (4) · Merck Sharp & Dohme LLC (4) · Affymax (3) · M.D. Anderson Cancer Center (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Pfizer (3) · St. Jude Children's Research Hospital (3) · Aevi Genomic Medicine, LLC, a Cerecor company (2) · Alexion Pharmaceuticals, Inc. (2) · Amgen (2) · Bellicum Pharmaceuticals (2)
United States (115) · United Kingdom (18) · Italy (14) · Germany (9) · France (8) · Canada (7) · Lebanon (6) · Greece (4) · South Korea (4) · Spain (4) · Turkey (Türkiye) (4) · Australia (3) · Austria (3) · Hungary (3) · South Africa (3)
Adrianna Vlachos, MD (2) · Kenneth I Ataga, MD (2) · Shany Blum, MD PhD (2) · Stanley Schrier, MD (2) · Vice President, Clinical Development (2) · Vivien Sheehan, MD (2) · William Ershler, MD (2)
PMID 36791280, PMID 42749863, PMID 14550808, PMID 16651647, PMID 17602062, PMID 19139736, PMID 21275961, PMID 21527519, PMID 21874061, PMID 21900080, PMID 22766223, PMID 22983573, PMID 23973010, PMID 24677033, PMID 24988120, PMID 25459642, PMID 25824692, PMID 26053664, PMID 26370220, PMID 30878319, PMID 31322833, PMID 34014839, PMID 34219224, PMID 34852172, PMID 34932836, PMID 34990411, PMID 35007144, PMID 35451176, PMID 36005278, PMID 37254256, PMID 37439373, PMID 37534517, PMID 37975597, PMID 38227447, PMID 39428602, PMID 40277027, PMID 40419809, PMID 41114449, PMID 41124654, PMID 41366634, PMID 41569644, PMID 41950571, PMID 42224366, PMID 42241700
P30CA015704 (5), 2019 (3), 2005 (2), 2014 (2), U01AG034661 (2), 2008 (1), 2009 (1), 2016 (1), 2017 (1), K23HL127100 (1), P01CA015396 (1), P01CA018029 (1), P01HL122173 (1), P20GM109021 (1), P30CA006973 (1)